Global Antibody Drug Conjugates Market to Surge from USD 12.26 Billion in 2024 to USD 32.11 Billion by 2033

Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Urothelial Carcinoma, Ovarian Cancer, Breast Cancer, Other Cancer), Product, Payload, Technology, Distribution Channel and Region with Growth Forecasts, 2025-2033" has been added to ResearchAndMarkets.com's offering.

The global antibody-drug conjugates (ADCs) market is on a robust growth trajectory, with a projected market size of USD 32.11 billion by 2033, from USD 12.26 billion in 2024. This translates to a compound annual growth rate (CAGR) of 10.49% from 2025 to 2033. This dynamic expansion is driven chiefly by the increasing prevalence of cancer and the escalating demand for targeted therapies that maximize efficacy and minimize systemic toxicity.

Recent advancements in targeted therapies, coupled with a surge in clinical trials and strategic investments from pharmaceutical giants, are propelling the ADC market forward. Ongoing research and development, particularly in targeted therapy and precision medicine, have bolstered the appeal of ADCs, positioning them as a preferred oncology treatment option.

The global rise in cancer incidence necessitates the development of therapies known for high efficacy and reduced adverse effects. ADCs meet these needs by targeting cancer cells directly, minimizing damage to healthy cells, thus enhancing patient outcomes. The increasing number of clinical trials and regulatory endorsements signify significant commitment levels from pharmaceutical companies to innovate in this arena.

Industry milestones include the approval of Datroway (datopotamab deruxtecan) in June 2025 by the U.S., earmarking it for advanced non-small cell lung cancer in pre-treated adults. Similarly, in February 2025, the FDA greenlit Datroway for certain breast cancer treatments. Additionally, GSK's Blenrep received regulatory approval in the UK for treating multiple myeloma in April 2025. These approvals underscore the growing validation and reliance on ADC therapies in the healthcare sector.

Global Antibody Drug Conjugates Market Report Segmentation

This report offers a comprehensive revenue growth forecast at global, regional, and country levels, analyzing the latest trends across sub-segments from 2021 to 2033. It segments the global ADC market by application, product, payload, technology, distribution channel, and region:

Application Outlook (Revenue, USD Million, 2021-2033)

Product Outlook (Revenue, USD Million, 2021-2033)

Payload Outlook (Revenue, USD Million, 2021-2033)

Technology Outlook (Revenue, USD Million, 2021-2033)

Distribution Channel Outlook (Revenue, USD Million, 2021-2033)

Regional Outlook (Revenue, USD Million, 2021-2033)

Why should you buy this report?

This report addresses:

Key Attributes:

Companies Featured

The key companies profiled in this Antibody Drug Conjugates market report include:

For more information about this report visit https://www.researchandmarkets.com/r/yzowel

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment